This area of research is still evolving, and more long-term human studies are needed
Pregnant or breastfeeding individuals should avoid it, too
In the ATTAIN-MAINTAIN trial, orforglipron's profile was "consistent with previous orforglipron Phase 3 studies." The most common adverse events were gastrointestinal-related and were generally mild-to-moderate in severity, which is expected for the GLP-1 class
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
Heres a quick breakdown our team put together to visualize the differences: So, for sciatica, which one makes more sense
Nausea, vomiting, diarrhea, constipation, and injection site reactions all appear in the safety data with frequency numbers attached